RAP1A and neoplasm: Furthermore, targeting CATED expression with a specific ASO restored tumor sensitivity to cisplatin in a DHX36‐RAP1A‐MAPK manner, indicating that CATED may serve as a potential therapeutic target for the treatment of platinum resistance in HGSOC (Figure 9g).